Breast cancer
Adult: 25-50 mg/m2 BSA every 3-4 wk, to be given as inj over 5-10 minutes into a rapidly-flowing infusion of glucose 5%.
Indications and Dosage
Intravenous
Breast cancer Adult: 25-50 mg/m2 BSA every 3-4 wk, to be given as inj over 5-10 minutes into a rapidly-flowing infusion of glucose 5%.
|
Contraindications
Cardiac disease. Pregnancy.
|
Special Precautions
Extravasation. Monitor cardiac function and blood counts. Hepatic impairment. Not to be given IM or SC. Check left ventricular ejection fraction before every course for doses >600 mg/m2.
|
Adverse Reactions
Moderate to severe nausea, vomiting and stomatitis; facial flushing, conjunctivitis and lachrymation; alopoecia; red coloration of urine; hypersensitivity reactions and hyperuricaemia.
Potentially Fatal: Pronounced bone-marrow suppression (dose-limiting), cardiac toxicity. |
Drug Interactions
Reduced absorption of digoxin tablets. Increased risk of low WBC counts when used with clozapine. Increased risk of cardiotoxicity when used with mitomycin.
|
Action
Description: Pirarubicin, a structural analogue of doxorubicin and with similar properties, forms stable complexes with DNA and interferes with nucleic acid synthesis.
|
MIMS Class
|